Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma ...

PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.

Pfizer (NYSE:PFE) received its first Chinese approval for obesity drug Severwin, opening access to a major new treatment ...

Sales of Pfizer's COVID-19 products have collapsed. Thanks to heavy investment fueled by COVID-related revenue, Pfizer has a big pipeline of new potential blockbuster drugs. Cancer treatments Pfizer ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...

China's National Medical Products Administration has approved Pfizer Inc.’s PFE ecnoglutide injection for chronic weight management in adults with overweight or obesity, marking the first approval of ...

Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation ...

Pfizer has demonstrated remarkable financial resilience in its latest quarterly report, significantly outpacing Wall Street expectations across key metrics. The pharmaceutical powerhouse announced ...